Research programme: dermal-derived cell therapies - Fibrocell Science/University of California at Los Angeles

Drug Profile

Research programme: dermal-derived cell therapies - Fibrocell Science/University of California at Los Angeles

Alternative Names: Autologous dermal fibroblast cell therapies - Fibrocell Science/UCLA; Autologous dermal mesenchymal adult stem cell therapies - Fibrocell Science/UCLA; Autologous dermal SERA cell therapies - Fibrocell Science/UCLA; Autologous dermal SSEA3-expressing regeneration-associated cell therapies - Fibrocell Science/UCLA

Latest Information Update: 19 Jun 2014

Price : $50

At a glance

  • Originator Fibrocell Science; University of California at Los Angeles
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders; Unspecified

Most Recent Events

  • 17 Jun 2014 Fibrocell Science and the University of California at Los Angeles enter into an exclusive license agreement for Fibrocell to acquire rights for commercial applications of patented discoveries for personalised cell therapies
  • 11 Jul 2013 Early research is ongoing in USA
  • 09 Mar 2011 Early research in Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top